Navigation Links
Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation

porine, methotrexate or PUVA (psoralen plus ultraviolet A light).

In February 2006, REMICADE was approved in the EU for the treatment of moderately-to-severely active UC in patients who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP or azathioprine, or who are intolerant to or have medical contraindications for such therapies. This approval made REMICADE the first and only biologic therapy approved to treat moderate-to-severe UC in the EU. In May 2007, REMICADE was approved in the EU for the treatment of severe, active Crohn's disease (CD) in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolert to, or have contraindications for, such therapies.

REMICADE is the only anti-TNF biologic therapy available as an IV form. Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. In RA (3 mg/kg), CD (5 mg/kg), PsA (5 mg/kg), UC (5 mg/kg), PCD (5 mg/kg), and PsO (5 mg/kg), REMICADE is a two-hour infusion administered every 8 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year. In AS (5 mg/kg), REMICADE is a two-hour infusion administered every 6 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6.

Centocor discovered REMICADE and has exclusive marketing rights to the product in the United States.

Schering-Plough markets REMICADE in all countries outside of the United States, except in Japan and parts of the Far East where Tanabe Seiyaku, Ltd. markets the product and in China where Xian-Janssen markets REMICADE.

Important Safety Information

There are reports of serious inf
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
2. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
3. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
6. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
7. Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation
Post Your Comments:
(Date:2/9/2010)... February 9 Debiopharm ... companies with,a focus on the development of ... announced the signature of an exclusive licence ... commercialisation of Debio 025,(alisporivir), a selective, first-in-class ... virus (HCV) effect. The product is currently ...
(Date:2/8/2010)... , Feb. 8 Cost reductions ... Products (Nasdaq: AHPI ) narrowly back into profitability ... Sales for the quarter ended December 31, 2009 ... million during the same quarter last year to ... Allied,s costs of sales were reduced even more sharply, ...
(Date:2/8/2010)... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... for the fourth quarter and year-end 2009 following the ... 2010 . ,, Paul Hamelin , President ... Officer, will host an investment community conference call beginning ... February 26, 2010 to discuss these results and ...
Breaking Medicine Technology:Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 2Impact Factor names Cell top research journal 8967 1Rotary Marks Progress in Drive to Eradicate Polio 49766 1Rotary Marks Progress in Drive to Eradicate Polio 49766 2Rotary Marks Progress in Drive to Eradicate Polio 49766 3ASAP Systems Launches New Depreciation Feature Enabling its Customers to Develop Custom Formulas to Calculate Depreciation Of Their Fixed Assets Inven 49762 1ASAP Systems Launches New Depreciation Feature Enabling its Customers to Develop Custom Formulas to Calculate Depreciation Of Their Fixed Assets Inven 49762 2
... Therapeutics Limited,one of the UK,s leading pre-IPO biotechnology ... study with its oral, once-daily experimental,cancer therapy CHR-2797 ... (AML), myelodysplastic syndromes (MDS) and multiple myeloma (MM),who ... chemotherapy., Headline data from the study, which ...
... CARLOS, Calif., Dec. 12 Nuvelo, Inc.,(Nasdaq: ... patient in a Phase 2,proof-of-concept trial of alfimeprase ... has also been granted fast track designation by ... in this indication. Fast,track designation, which was mandated ...
Other Medicine Technology:Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 3Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 4
(Date:2/9/2010)... to about 300,000 Children and Families, , ... ... One month after Haiti experienced the worst natural disaster in ... and adults in the earthquake impact zone. , , , ... humanitarian agency has been providing emergency assistance to save lives, ...
(Date:2/9/2010)... lost much more weight than peers who tried lifestyle ... obese teens who received gastric banding surgery lost significantly ... as dieting and exercise, Australian researchers report. , Their ... a body-mass index (BMI) higher than 35 (statistical obesity ... adjustable gastric banding while the other half took part ...
(Date:2/9/2010)... found larger, for-profit hospitals more likely to insert them ... and those that are set up to make a ... patients with advanced dementia, despite evidence that the practice ... and other problems. , "Our results suggest that decisions ... go to than a decision-making process that really elicits ...
(Date:2/9/2010)... SAINT PAUL, Minn. , Feb. 9 ... death, chronic obstructive pulmonary disease (COPD), is now ... Environmental Public Health Tracking Program. The program focuses ... Minnesota that can be triggered or made ... or outdoor air pollution — asthma, heart attacks ...
(Date:2/9/2010)... a Gift for ... ,, CHICAGO , Feb. 9 /PRNewswire-USNewswire/ ... by giving a gift for the heart ... Fast, and Flavorful Recipes Made with Canola Oil" by ... cook some of these recipes for love or give ...
Breaking Medicine News(10 mins):Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 2Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 3Health News:Gastric Banding Most Effective for Obese Teens 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 3Health News:Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3
... Visions, Inc., a premier,event production and audio-visual integration ... was acquired by Interactive Holdings, a leading,communication solutions ... Creative Visions is best known for producing world ... Palace of Versailles, Sydney Opera House,Blenheim Palace and ...
... Paramedics and emergency medical technicians (EMTs) employed by ... members of Teamsters Local 375 attended the company,s annual ... Employee shareholders expressed their frustration with the company,s reluctance ... new contract in the greater Buffalo, New York area, ...
... Newsletter Series for Physicians , , ... difficile infection (CDI) in geriatric and ... observed increase in CDI incidence in many age groups, healthcare ... of these patient populations. , , ...
... corporate leaders joined together today to unveil the new Houston ... a model for other cities also struggling with the crisis ... The clinic is a joint project between janitors and responsible ... Baylor College of Medicine -- to make health care ...
... /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: CHDX ... healthcare,products and services in the People,s Republic of ... offered not to accept any increases in,their respective ... for fiscal 2009. This unsolicited offer has ...
... at same dosage used to improve cognitive impairment, ... -- Drugs used to treat Alzheimer,s patients, cognitive ... for behavioral and psychological symptoms such as aggression, ... , They reviewed nine studies that examined the ...
Other Medicine News:Health News:Creative Visions Acquired by Interactive Holdings 2Health News:Creative Visions Acquired by Interactive Holdings 3Health News:Current Concepts in Clostridium difficile Infection: A Focus on Geriatric and Pediatric Patients 2Health News:SEIU Janitors and Responsible Corporate Leaders Herald New Model for Making Health Care More Accessible and More Affordable 2Health News:Chindex International, Inc. Adopts Voluntary Executive Compensation Restrictions 2Health News:Chindex International, Inc. Adopts Voluntary Executive Compensation Restrictions 3Health News:Alzheimer's Drugs Also Treat Behavioral, Psych Problems 2
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
... Off-white free flowing powder. pH: pH(4.7%, ... Casein Peptone: 24% Yeast Extract: 47% Potassium Phosphate ... To Use: Dissolve 47 gm powder per liter ... of plasmid DNA and recombinant proteins than LB ...
...
Medicine Products: